Developing new medicines that harness the building blocks of life to work in harmony with the body’s immune system

Learn more about IMUNON’s
Phase II Ovarian Cancer clinical trial, 
which is now enrolling.

Our Breakthroughs

Imunon is developing new medicines that harness the building blocks of life to work in harmony with the body’s immune system. Imunon creates proprietary immunology and DNA-based platforms and products aimed at some of the world’s most difficult-to-treat conditions.

Leadership

Our senior executives have 50+ combined years of experience in research, innovation, and capital management at some of the world’s most recognized companies.

Khursheed Anwer, EVP & CSO

Jeffrey W. Church, EVP & CFO

0

million

people lose their lives to vaccine-preventable diseases every year - our clinical development of anti-cancer nucleic acid-based therapies and nucleic acid vaccines for infectious diseases and cancer is about being bold and solving the world's biggest problems. Because every person deserves the opportunity to live a full life.

0

combined years of leadership experience in the biotech industry

0 +

key partners, including the world’s most respected research institutions

0

products in the pipeline with an addressable market worth $15B+ 

What's New

October 23–25, 2023  | Boston, MA

Dr. Khursheed Anwer will deliver an oral presentation on A DNA-Based Vaccine Technology Independent Of A Virus Or Device

Contact Us

If you’re interested in partnering with us on an upcoming project, we’d love to hear from you.

Kursheed Anwer

Khursheed Anwer, PhD, MBA

Executive Vice President and Chief Science Officer

Khursheed Anwer, PhD, MBA, assumed the title of Executive Vice President and Chief Science Officer, upon Imunon’s June 2014 acquisition of EGEN, Inc., where he was President and Chief Science Officer, a position he held since 2009. He joined EGEN, Inc. in July, 2002, as Vice President of Research and Development, and directed the company’s clinical and research and development functions throughout his tenure at EGEN, Inc. Dr. Anwer has a PhD in Physiology/Pharmacology from Ohio University and received postdoctoral training from the University of Texas Health Science Center at Houston. Before joining EGEN, Inc., Dr. Anwer was Director of Pre-Clinical Development at Valentis, Inc. From 1993 to 1999, he served in several positions at GeneMedicine, Inc., where he led several research projects in the area of nonviral gene therapy. He has authored more than 40 publications in the area of nonviral gene therapy, resulting from his active career in research and development. Dr. Anwer has served as an adjunct faculty member in the Biology Department at the University of Alabama in Huntsville and a board member of the University of Alabama Business School, STEP.

Jeffrey Church

Jeffrey W. Church

Executive Vice President, Chief Financial Officer and Corporate Secretary

Jeffrey W. Church was appointed Senior Vice President and Chief Financial Officer of Imunon in July 2013. The appointment marked Mr. Church’s resumption of the role of Chief Financial Officer, a position he held prior to his promotion to Senior Vice President in July 2011, while also granting him responsibility for corporate investor relations. Mr. Church joined Imunon in July 2010 as Vice President and Chief Financial Officer. He brings more than 30 years of experience in corporate finance, mergers and acquisitions, investor relations, and SEC reporting. Prior to joining Imunon, Mr. Church held senior financial executive positions with several private and public clinical-stage life science companies, including Alba Therapeutics Corporation, Novavax, Inc., GenVec, Inc., and Meridian Medical Technologies, Inc. Mr. Church started his career in 1979 with the public accounting firm Price Waterhouse. Mr. Church holds a BS degree from the University of Maryland and received his Maryland Certified Public Accountant accreditation in 1979.

Corinne Le Goff

Corinne Le Goff, Pharm. D., MBA

President, Chief Executive Officer and Director

Dr. Le Goff was appointed President, Chief Executive Officer and Director of Imunon and elected to the Board of Directors on July 18, 2022.   Dr. Le Goff brings decades of global healthcare leadership experience to the Company across a range of therapeutic areas including oncology, vaccines, immunology, CNS and cardio-metabolism. She brings a wealth of experience in developing and launching successful drugs from her tenure at both large, pharmaceutical companies and small, innovative biotech companies.  Prior to her Imunon appointment, Dr. Corinne Le Goff most recently served as the Chief Commercial Officer of Moderna, and was responsible for developing the global presence and capabilities necessary to ensure the global distribution of Moderna’s COVID-19 vaccine. She also led the development of the mRNA platform long-term commercial strategy. Dr. Le Goff joined Moderna from Amgen, where she served as President of the U.S. Business, driving the growth strategy with increased contributions from Repatha® and Aimovig®. During her nearly 6-year tenure at Amgen, she also served as Senior Vice President of Global Product Strategy & Commercial Innovation and as President of the Europe Region overseeing 48 markets. Dr. Le Goff was actively engaged with the policy community and advocates for innovative, high-quality and affordable healthcare. She represented Amgen as a member of the Healthcare Leadership Council. Prior to joining Amgen, Dr. Le Goff held a number of senior international roles at Roche, including President of Roche France, a major affiliate of the Roche Group, and Global Product Strategy Head of Neuroscience & Rare Diseases. Early in her career, Dr. Le Goff spent 11 years in various leadership roles at Sanofi and Pfizer in the United States.Dr. Le Goff earned a Doctorate in Pharmacy from Rene Descartes University in Paris and an MBA from Sorbonne University and INSEAD. She also holds qualifications from Northwestern University and the Hong Kong University of Science and Technology. She received the distinction of being named a Chevalier de la Légion d’Honneur in 2014.